Cord Blood Day One


Cord Blood Day 1- Wednesday 16th May 2018


08:00 Registration opens

Opening Keynotes: Innovative Applications of Cord Blood

Cord Blood Plenary

Welcome from Terrapinn

Cord Blood Plenary

Evaluating the efficacy of umbilical cord blood to improve outcomes for children with Autism

  •     An update from Joanne’s latest clinical trials
  •     Umbilical cord blood-derived cell therapies may have potential in alleviating ASD symptoms by modulating inflammatory processes in the brain
  •     Looking to the future of cord blood clinical use
Cord Blood Plenary

Off-the-shelf CAR-engineered cord blood derived natural killer cells to treat cancer

  • Discuss approaches for the GMP grade expansion of cord blood derived natural killer cells for cellular therapy
  • Discuss strategies to engineer cord blood derived natural killer cells to enhance their anti-tumor potency and in vivo persistence
  • Present data on the first-in-human clinical trial of off-the-shelf CAR-engineered cord blood derived natural killer cells

Networking Refreshment Break

Cord Blood Plenary

Round Table Discussion Session


Networking Lunch

Collection, Bioprocessing and Storage

Cord Blood Plenary

Cord blood expansion for engraftment and regenerative medicine

  • Current state of the art for cord blood expansion in the transplant setting
  • MSCs for regenerative medicine and GVHD
  • Will discuss the GMP production of cord blood tissue derived MSCs for clinical use
Cord Blood Plenary

An effective logistical case study for stem cell collection, storage and use in Thailand

  •     The challenges of storing, collecting and processing stem cells in South East Asia
  •     Overview of processes and how challenges can be overcome
  •     Successful case studies
Cord Blood Plenary

Timing of cord clamping and impact on cord blood collection

  •     Delayed clamping of the umbilical cord after birth has been a subject of controversy and debate
  •     Overview of evidence 
  •     Suggested Industry responsibility and actions 

Networking Refreshment Break

Expansion and Engraftment

Cord Blood Plenary

The safety and efficacy of human placental derived stem cells in combination with unrelated cord blood transplantation in children

  • Background on UCBT and HPDSC
  • Hematopoietic engraftment following UCBT & HPDSC
  • Immune Reconstitution following UCBT & HPDSC
  • Probability of Acute and Chronic GVHD following UCBT & HPDSC
Cord Blood Plenary

The science behind ex vivo manipulation of CB HSCs for transplantation

  •     A consultant haematologist at UCLH and a Senior Lecturer at the UCL Cancer institute: his interests include understanding cell fate choices in haematopoietic stem cells
  •     Rajeev Gupta is currently carrying out some fascinating work encompassing pre-treating CB HSCs with various techniques, and studying those effects on engraftment 
Cord Blood Plenary

NiCord® Breakthrough Therapy Designation - addressing the unmet need in BMT with a novel graft modality

  • NiCord is an ex vivo expanded cell graft derived from umbilical cord stem cells 
  • A phase 3 randomized controlled multi-national registration study is enrolling patients
  • NiCord is expected to double the number of indicated patients to transplant
Cord Blood Plenary

Ex vivo expansion of cord blood hematopoietic stem cells - from formulation to manufacturing process CombiCult- combinatorial cell culture as a platform to find optimal media compositions for the stem

  • Application of CombiCult for HSC expansion
  • Identification of media formulations that enrich the HSC compartment
  • In vitro analysis of expanded cells
  • Identification of GMP-compliant processes for HSC cell expansion

Offsite Networking Drinks

last published: 16/Mar/18 11:35 GMT




World Advanced Therapies & Regenerative Medicine Congress


Erica Baeta
+44 (0)207 092 1152


Jessica Robinson
t/ +44 (0)207 092 1150


Issa Mauthoor
+44 (0)207 092 1257